Plesner has assisted Zealand Pharma A/S with a successful equity raise
Plesner has assisted our long-time client Zealand Pharma with an equity raise of approximately DKK 749 million through a directed issue and private placement of new ordinary shares. The equity raise qualifies as the largest equity raise Zealand Pharma has ever completed.
On 27 January 2021, Zealand Pharma, a company listed on Nasdaq Copenhagen and the Nasdaq Global Select Market in New York, launched and completed a successful offering of new shares at a price of DKK 208 per new share, raising gross proceeds of DKK 749 million and welcoming strong new institutional investors.
Plesner is proud to have assisted our long-time client, Zealand Pharma, with the important milestone equity raise.
The proceeds enable Zealand to continue its focus on the discovery, development, and commercialization of next generation peptide-based medicines and goal to provide meaningful and life changing medicines to patients and families suffering from life altering metabolic and gastrointestinal diseases.
Specifically, the proceeds of the offering will help fund Zealand Pharma's ambition to commercialize its late stage product candidates, expand its research capabilities within its peptide platform and accelerate other clinical development.
Goldman Sachs International, Jefferies International and Danske Bank acted as joint global coordinators and joint bookrunners. Bryan, Garnier & Co and Nordea Danmark acted as co-managers.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA).